Table 2.

Risk of glioma by recency, type and form of hormonal contraceptive use by women aged 15–49 years

Contraceptive use	Cases	Controls	Crude odds ratioa (95% CI)	Adjusted odds ratiob (95% CI)
Non-use	131	1061	1 (reference)	1 (reference)
Ever use	186	1065	1.5 (1.2, 2.0)	1.5 (1.2, 2.0)
Current/recentc	147	791	1.7 (1.3, 2.3)	1.7 (1.3, 2.4)
Pastd	39	274	1.2 (0.8, 2.0)	1.2 (0.8, 2.0)
Type and form
Oestrogen and progestagen onlye	145	895	1.4 (1.0, 1.8)	1.4 (1.0, 1.8)
Tablet onlyf	142	890	1.4 (1.0, 1.8)	1.4 (1.0, 1.8)
Progestagen onlye	21	76	2.9 (1.6, 5.2)	2.8 (1.6, 5.1)
Tablet onlyf	14	34	3.3 (1.6, 6.9)	3.2 (1.5, 6.8)
IUDg onlyf	6	38	2.4 (0.8, 6.8)	2.4 (0.8, 6.8)
Mixed useh	20	94	1.6 (0.8, 3.0)	1.5 (0.8, 3.0)

^aAdjusted for age and calendar year by design.

^bAdditionally adjusted for schooling and hospital contacts for allergy and asthma.

^cLast prescription for contraceptive dispensed <5 years prior to index date.

^dLast prescription for contraceptive dispensed ≥5 years prior to index date.

^eOnly use of a single type of contraceptive recorded in Prescription Registry.

^fOnly use of a single form of contraceptive recorded in Prescription Registry.

^gIntrauterine device.

^hMore than one type of contraceptive recorded in Prescription Registry.